Promising new treatments for neovascular age-related macular degeneration.
about
Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical applicationIs IL-10 a good target to inhibit choroidal neovascularisation in age-related macular disease?A reproducible and quantifiable model of choroidal neovascularization induced by VEGF A165 after subretinal adenoviral gene transfer in the rabbit.Age-related macular degeneration: current treatments.An efficient synthetic strategy for obtaining 4-methoxy carbon isotope labeled combretastatin A-4 phosphate and other Z-combretastatins.Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization.A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration.Cell-penetrating peptide for enhanced delivery of nucleic acids and drugs to ocular tissues including retina and corneaOne-Year Feasibility Study of Replenish MicroPump for Intravitreal Drug Delivery: A Pilot Study.The α7-nicotinic acetylcholine receptor and MMP-2/-9 pathway mediate the proangiogenic effect of nicotine in human retinal endothelial cells.In vivo ocular fluorophotometry: delivery of fluoresceinated dextrans via transscleral diffusion in rabbits.Fibrosis and diseases of the eye.Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodiesUse of optical coherence tomography, fluorescein angiography and indocyanine green angiography in a screening clinic for wet age-related macular degeneration.Prevention of VEGF-induced growth and tube formation in human retinal endothelial cells by aldose reductase inhibitionNew therapeutic targets in atrophic age-related macular degeneration.Novel delivery methods to achieve immunomodulation.Synthetic delivery systems for intravenous administration of nucleic acids.The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge.Lentiviral vector-mediated RNA silencing in the central nervous system.Lentiviral vectors encoding short hairpin RNAs efficiently transduce and knockdown LINGO-1 but induce an interferon response and cytotoxicity in central nervous system neurones.Innate immunity confounds the clinical efficacy of small interfering RNAs (siRNAs).PlGF gene knockdown in human retinal pigment epithelial cells.Placental growth factor promotes epithelial-mesenchymal transition-like changes in ARPE-19 cells under hypoxia.
P2860
Q28082140-69A1AE5C-C821-4137-BC32-8F394F65CFD1Q33253662-E3F6DFBD-612D-4B50-B132-143949DDA43BQ33358094-C14EBAF2-520C-4EEF-A3F7-9B28DF89E6ADQ33492348-F043FE93-15A2-4753-A7AD-574706B27CF6Q33823154-97F084A4-D391-4DFF-AD15-8F872B69DB80Q33880596-12F6D037-BCFF-4F26-B5B2-65EABB11AFCEQ33892696-E2F0FA68-4CC5-4D78-958B-86C2FF28E949Q34093606-925B32FE-144C-4EE6-99B0-C804F9926A0AQ35167647-2049FB1C-B2DF-42E7-9AC8-2FC93D17EDC8Q35221001-B8B3F6F0-42C6-489B-8A2B-F6BF083B6835Q35518911-D6D53269-CA13-4E03-9A0D-AFFA17EAB350Q35649477-54E8AB01-BF22-4B8B-8BA9-F9F658E51877Q35652113-ECE93FAD-36D3-4C6A-9A6C-037100F729E9Q35953633-CD4A3FB9-D167-4817-B381-0F63AED50C8DQ36209915-4A8E9C3A-4AD5-4CCB-937C-63569D52FA3AQ36804427-A450E271-1BBA-4927-B614-DE221CFD8202Q36870418-A6D73A8B-D914-497D-919B-E4A3A53678EAQ36917917-FD4DDD9B-0621-402A-977F-E8BD1204FD91Q38101684-BD55B105-A747-4ADC-A541-6A3AEB06A526Q38148784-0FF6722B-8BD7-4A40-AC0C-8A5D782065ACQ38463583-99BBCC31-331A-40C7-B10C-E4BE4B448E75Q45883610-215473DB-356D-48FB-BF3D-5F30275887C9Q54400583-AE27CC88-3445-4BD4-A6C1-1FBABFE597A7Q54957577-D1DB19D0-50FA-4E1F-87E2-B915B37CC953
P2860
Promising new treatments for neovascular age-related macular degeneration.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Promising new treatments for neovascular age-related macular degeneration.
@ast
Promising new treatments for neovascular age-related macular degeneration.
@en
type
label
Promising new treatments for neovascular age-related macular degeneration.
@ast
Promising new treatments for neovascular age-related macular degeneration.
@en
prefLabel
Promising new treatments for neovascular age-related macular degeneration.
@ast
Promising new treatments for neovascular age-related macular degeneration.
@en
P2860
P1476
Promising new treatments for neovascular age-related macular degeneration.
@en
P2093
Philip J Rosenfeld
Stephan Michels
P2860
P304
P356
10.1517/13543784.15.7.779
P407
P577
2006-07-01T00:00:00Z